Fracture-Related Safety Reporting of JAK Inhibitors: An Analysis from the WHO Global VigiBase
The results from this pharmacovigilance analysis, based on a spontaneous reporting database associated with inherent limitations, suggest a potential risk of fractures with JAK inhibitors, indicating that a class effect cannot be ruled out.
Authors
- Stefan Weiler (ORCID: https://orcid.org/0000-0003-1087-7597)
- Adrián Martínez-De la Torre (ORCID: https://orcid.org/0000-0002-3155-7421)
- Angela Clausen
- Andrea M. Burden (ORCID: https://orcid.org/0000-0001-7082-8530)
Institutions
- University of Copenhagen (DK)
- University of Zurich (CH)
- ETH Zurich (CH)
- University Hospital of Zurich (CH)
Publication Details
- Journal
- Drug Safety
- Published
- 2024-11-27
- DOI
- https://doi.org/10.1007/s40264-024-01490-w
- Citations
- 4
- Primary Topic
- Cytokine Signaling Pathways and Interactions
- Type
- article
- Field-Weighted Citation Impact
- 1.13
Funders
- Eidgenössische Technische Hochschule Zürich
- Novo Nordisk
- Nordea-fonden
- Novo Nordisk Fonden